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EDITORIAL

The Development and Growth of Cardio-oncology or
Onco-cardiology*
Bernard Man Yung Cheung*, Chu Pak Lau
Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Hong Kong, China

B

esides infectious diseases, cardiovascular (CV)
diseases and cancer are the two major causes of
death. The direct and indirect relationships between
CV diseases and cancer are increasingly recognised
(Table 1) [1]. Firstly, they tend to be more common
in older people, and there are some shared aetiologies, such as tobacco use and obesity. Secondly,
there are some common pathogenetic mechanisms,
such as inﬂammation and thrombosis. Thirdly, patients with CV diseases have a higher rate of cancer
while conversely, cancer patients have a higher rate
of CV diseases. This is important because as cancer
survival improves with newer cancer treatments,
these survivors are at risk of dying from CV diseases. Fourthly, many cancer treatments, including
radiotherapy, cytotoxic chemotherapy, targeted
therapy, immunotherapy and CAR-T therapy have
CV adverse effects (Table 2) [2]. Since cancer is a
serious and often life-threatening condition, doctors
and patients accept a higher level of risk and
adverse effects because of the potential beneﬁts in
Table 1. Cardio-oncology syndromes [1].
1.
2.
3.
4.

Cancer causing CV diseases
Cancer treatment causing CV diseases
CV diseases causing a pro-oncogenic environment
CVD treatment and diagnostics causing a pro-oncogenic
environment
5. Genetic and systemic conditions causing both cancer and CV
diseases
CV ¼ Cardiovascular.

extending lifespan. Thus, instead of avoiding or
withdrawing a drug because of its potential or actual
adverse effects, both the patient and the doctor often
agree to proceed with the cancer treatment. Here,
the selection of dose and frequency, and monitoring
of adverse effects become important.
In this issue, Lam TH et al. reported a small case
series of cancer patients who received an immune
checkpoint inhibitor and developed myocarditis [3].
While similar cases have been reported before, this
report highlights the growing need to monitor CV
and other adverse effects of these relatively new
cancer drugs, and the need to accumulate experience and expertise on preventing and treating these
adverse effects.
Prevention is better than cure, therefore it is
preferable to recognise any cancer therapy related
CV complications before they become clinically
manifest, in order for the therapy to be withheld or
dosages adjusted. Better still, identiﬁcation of high
risk phenotypic/genotypic proﬁles in patients may,
a priori, allow precision cancer therapy prescription.
Several international guidelines [4e9] have recommended CV monitoring and therapy based on
expert consensus, as randomised data are scarce.
From the patients’ perspective, pre-existing CV diseases will increase the susceptibility to cancer therapy
related CV complications, as well as a history of prior
chemotherapy or radiotherapy (Table 3). CV risk and
the presence of CV risk factors should be assessed as a
baseline before starting cancer treatment. The CV risk
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Table 2. Cardiotoxicity associated with cancer drugs [2].
Anticancer agent
Anthracyclines
Doxorubicin
Epirubicin
Alkylating agents
Cisplatin
Antimetabolites
Fluorouracil
Capecitabine
Antimicrotubule agents
Docetaxel
Monoclonal antibodies
Rituximab
Ofatumumab
Alemtuzumab
Monoclonal antibodies (HER2)
Bevacizumab
Trastuzumab
Small-molecule TKIs
Dasatinib
Pazopanib
Ponatinib
Sorafenib
Sunitinib
Ibrutinib
Erlotinib
Cetuximab
Crizotinib
Immune checkpoint inhibitors
Nivolumab
Ipilimumab
Pembrolizumab
Protease inhibitors
Bortezomib
Carﬁlzomib
mTOR inhibitors
Everolimus
Temsirolimus
IMiDs
Lenalidomide
Thalidomide
Pomalidomide
Endocrine therapy
Selective ER modulators
 Tamoxifen
AIs
 Anastrozole
 Letrozole
 Exemestane
Chimeric antigen receptor (CAR) T Cell Therapy
Tisagenlecleucel
Axicabtagene ciloleucel

Type of cardiotoxicity
HF, Arrhythmia

VTE, HTN
Ischaemia, Arrhythmia
Ischaemia, Arrhythmia
HF, LVD, Arrhythmia
Hypotension infusion reaction, HTN

HTN, VTE
HF
ACS, HF, QT prolongation, pulmonary HT
HTN, Bradyarrhythmia, HF
HF, HTN, Ischaemia, ATE, VTE
HTN, HF, Ischaemia
HTN, HF, VTE
Atrial ﬁbrillation, HTN, Bleeding
VTE
Bradyarrhythmia, QT prolongation
Myocarditis, Arrhythmia, LVD, SCD, Vasculitis, Pericarditis

HTN
HF, VTE, HTN, ACS
HTN
HTN
VTE

VTE, QT prolongation
VTE, HTN, Hyperlipidaemia

Tachycardia, Arrhythmia, Hypotension, HTN, HF
Capillary leak syndrome
MI (unrelated to CAD, likely due to antigen mimicry)

ACS, acute coronary syndrome; AI, aromatase inhibitor; ATE, arterial thromboembolism; CAD, coronary artery disease; CV, cardiovascular; CVA, cerebrovascular accident; ER, oestrogen receptor; HER2, human epidermal growth factor receptor 2; HF, heart failure;
HTN, hypertension; IMiD, immunomodulatory drug; LVD, left ventricular dysfunction; MI, myocardial infarction; mTOR, mammalian
target of rapamycin; QT, corrected QT interval (preferably by Fridericia's formula); SCD, sudden cardiac death; TKI, tyrosine kinase
inhibitor; VTE, venous thromboembolism.

factors that are particularly relevant are blood pressure, lipids and glucose. Apart from clinical assessment of both the CV system and other comorbidities,

resting ECGs to evaluate and monitor the rhythm and
QTc interval are also important. Troponin and NTproBNP level changes are often regarded as markers

104

J HK COLL CARDIOL 2022;29(3):102e105

Table 3. Assessment of cancer therapy related cardiovascular complications.
Parameters

Assessment

Management

Age, CV and other medical co-morbidities

Clinical

History of prior chemotherapy
and radiotherapy
ECG

Information on total accumulated
dose and/or site applied
Rhythm
QTc
Troponin
NT-proBNP
Echo e.g. LVEF, GLS
CMR

Optimisation of co-morbidities condition and
risk factor control according to guidelines
Therapy selection and dose adjustment

Cardiac biomarkers
Left ventricular function

Avoid electrolytes disturbance
Monitor and therapy
Monitoring and early intervention
Monitoring and early intervention
Prophylactic heart failure therapy

Abbreviation: CMR ¼ cardiac magnetic resonance scan; CV ¼ cardiovascular; GLS ¼ global longitudinal strain; LVEF ¼ left ventricle
ejection fraction.

of early cardiac damage. Imaging of the left ventricular function (echocardiographic and cardiac magnetic resonance imaging scans) are often necessary.
For example, a reduction in left ventricular ejection
fraction (LVEF) > 10% (and to <50%) or >20% alone
are considered signiﬁcant CV complication. Global
longitudinal strain is regarded as a more sensitive
marker, and a 5% reduction is considered a signiﬁcant
change.
From the oncological therapy perspective, some
agents are associated with more CV complication
than others (Table 2) [2]. For example, anthracycline
dose-dependent cardiac complications are well
known to most cardiologists, with complications
occurring at  250 mg/m2 for doxorubicin and
600 mg/m2 for epirubicin [8]. Similarly, HER2 inhibitors such as trastuzumab may also cause heart
failure. Small-molecule tyrosine kinase inhibitors
such as dasatinib used for chronic myeloid
leukaemia can cause acute coronary syndrome and
pulmonary hypertension. The immune checkpoint
inhibitors, are implicated to cause myocarditis that
carries high fatality as applied in the report [3]. A
number of these drugs also cause atrial and ventricular arrhythmias [9]. Most guidelines recommend baseline CV evaluation, but there is yet no
consensus on the details and frequency of CVS reassessment during ongoing therapy. As these patients are under the care of oncologists who are
familiar with the side-effects of these agents, their
vigilance and timely notiﬁcation of cardiologists
when CV complications occur are critical.
Owing to specialization within medicine, few oncologists have cardiological training and conversely,
few cardiologists prescribe chemotherapy and other
oncology drugs regularly. Moreover, the number of
new drugs for cancer has proliferated at an unprecedented pace in the last decade, such that even
oncologists have difﬁculty keeping up with new
treatments and their usages. It is under these circumstances that in advanced countries, the

discipline of oncocardiology or cardio-oncology has
emerged. Cancer care has always been a multidisciplinary affair, with surgery, medicine, radiotherapy, anaesthesia (pain management) and
palliative medicine as its core. It now seems timely
to involve the cardiologist in this team, at least in
baseline assessment, and in well-timed periodic
monitoring.
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